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Traveler’s Infections: Overview of 
Hepatitis B Virus Infection
Victor B. Oti
Abstract
Hepatitis B virus (HBV) is a double-stranded circular DNA virus that infects 
the hepatocytes. HBV infection is considered as an important public health concern 
globally especially with one-third of the world’s population been infected. Local 
and international migrants are one of those population at high risk of the infec-
tion. Many factors interplay in the acquisition of HBV such as purpose of travel, 
destination endemicity rate of the virus, time of stay of the traveler, inadequate 
prevention and control measures, among others, understanding the genotypes of 
HBV is critical in correlating the evolution of the virus and migration of humans 
and also treatment responses of infected population. The symptom of the virus 
ranges from fever to jaundice and to a liver cirrhosis and hepatocellular carcinoma 
(HCC). Transmission of HBV is commonly via horizontal route in developing 
regions and in the developed regions; transmission occur more often among adults 
that use injectable drugs and high-risk sexual behaviors. Therefore, the Centers for 
Disease Control and Prevention (CDC) and World Health Organization (WHO) 
have recommended HBV screening and vaccination to all travelers without an HBV 
immunization history before traveling to endemic regions. This chapter gives an 
overview on HBV as a potential traveler’s infection.
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1. Introduction
Hepatitis B virus (HBV) is a partially double-stranded viral agent with a circular 
deoxyribose nucleic acid (DNA) that replicates by reverse transcription. HBV 
infection is a hepatocyte infection that is globally considered as a public health 
concern [1–3]. There are more than 2 billion persons infected with HBV living today 
worldwide with 260 million estimated to be chronically infected with the infection 
and having a carrier rate varying from 9 to 20% in Sub-Saharan Africa (SSA) [4–6]. 
Annually, there are close to 900,000 HBV-related deaths, mainly due to cirrhosis 
or hepatocellular carcinoma (HCC). The viral infection is the fourth most common 
vaccine preventable infection among travelers returning home ill after enteric fever, 
acute hepatitis A, and influenza [7, 8]. This viral agent can cause both acute and 
chronic infections. Many infected persons show no symptoms during the initial 
stage of the infection. Typically, the viral agent has an incubation period of 90 days 
(range, 60–150 days). The acute HBV infection that is acquired newly only shows 
symptoms rarely. Signs and symptoms of the viral infection differs with age; most 
children aged under 5 years old and newly infected immunosuppressed adults often 
show no symptoms, while about 30–50% of people that are more than 5 years of 
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Figure 1. 
Morphology of hepatitis B virus [16, 18].
age are usually symptomatic [7]. When present, the typical signs and symptoms of 
acute infection include malaise, fatigue, poor appetite, nausea, vomiting, abdominal 
pain, fever, dark urine, light color (clay-colored) stool, joint pain, and jaundice [8]. 
The overall case fatality ratio of acute infection due to HBV is approximately 1% [9]. 
People infected with HBV are susceptible to infection with hepatitis D virus; coin-
fection increases the risk of fulminant hepatitis and rapidly progressive liver disease 
[10]. Transmission of HBV is mainly through percutaneous or mucosal exposure to 
HBV-infected blood or bodily fluids including saliva or semen [2]. There are reports 
of transmission via sexual contact and contaminated medical equipment and 
through sharing of infected needles and injecting apparatus [11].
The prevalence of chronic HBV infection is ≥2%, such as in the western Pacific 
and African regions; expatriates, missionaries, and long-term development work-
ers may be at increased risk for HBV infection in such countries [7, 8]. Serologic 
markers specific for the viral agent are necessary to diagnose HBV infection and 
for appropriate clinical management [12]. These markers can differentiate between 
acute, resolving, and chronic infections. Polymerase chain reaction (PCR) method 
can further be use to qualitatively or quantitatively detect the amount of HBV DNA 
in patients’ specimen after checking the markers of the virus [13]. All travelers 
should be screened for HBV infection markers, so that they would not be at risk of 
acquiring the virus during their stay [7].
2. Aspects of HBV morphology
Hepatitis B virus belongs to the family of Hepadnaviridae in the genus 
Orthohepadnavirus, and it is known to have a very high transmissibility [14, 15]. It 
is a hepatotropic DNA virus which also includes duck hepatitis B virus (DHBV) and 
woodchuck hepatitis B virus (WHBV) [16]. HBV is partially double-stranded with 
a circular DNA that is composed of an outer envelope containing hepatitis B surface 
antigen (HBsAg) and an inner nucleocapsid consisting of hepatitis B envelope 
antigen (HBeAg) and hepatitis B core antigen (HBcAg) of approximately 3.2 kb, 
generated from an intermediate RNA through reverse transcription that encodes 
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four partially overlapping open reading frames (ORF): surface (S), encoding the 
viral surface protein; core (C) encoding core; polymerase protein; and pDNA and X 
genera as seen in Figure 1 [17, 18]. The virus infects the liver of Hominoidae includ-
ing humans and causes an inflammation called hepatitis. The disease was formally 
known as “serum hepatitis” [19].
3. How HBV replicates
The cardinal feature of HBV replication cycle is the replication of the DNA 
genome by reverse transcription, when virions bind susceptible cell-surface 
receptors and IgA receptors on liver cells following of RNA intermediate [18, 
20]. The viral genome is transported into the nucleus, and it is then converted 
into a covalently closed circular double-stranded HBV DNA (cccDNA) mol-
ecule which acts as the transcriptional template for the host RNA polymerase 
II machinery that synthesizes polyadenylated and four capped mRNAs which 
encode the envelope structural proteins, viral core and the precore; polymerase; 
and X non-structural viral proteins [20]. A 3.5-kb genome length RNA is one of 
the major HBV transcripts which is translated to synthesize the viral core and 
polymerase proteins and also plays role as a pregenomic RNA that is encapsid-
ated with the polymerase by the core protein in the cytoplasm of the liver cells. 
The replication of the viral agent usually happens entirely within these capsids 
by reverse transcription of the pregenomic RNA to synthesize a single-strand 
DNA copy that serves as the template for the second strand DNA produced, 
synthesizing a circular double-stranded DNA [21]. The viral capsids that con-
tain the double-stranded DNA traffic either to the nucleus where amplification 
occurs or the viral cccDNA genome to stabilize intranuclear pool of transcrip-
tional templates or to the endoplasmic reticulum, where they acquire the viral 
envelope proteins, bud into the lumen, and exit the cell as virions that can infect 
other cells [22, 23].
4. Pathogenesis and clinical features of HBV infection
Hepatitis B virus gets entry into the bloodstream and targets the liver cells [24]. 
The hepatocytes which are infected are distended, and the cytoplasm assumes a 
ground appearance that is glassy. The virus is not cytopathic, and injury of the liver 
in HBV chronic infection is due to immunological responses [8, 25]. Although, 
the virus has a long incubation period of 45–180 days, replication starts few days 
after infection. The infection can be acute, an unexpected sickness with a mild-to-
severe course followed by comprehensive resolve [26]. On the other hand, if the 
cell-mediated immune reaction is feeble, the infection does not resolve, and chronic 
hepatitis arises with an extended course of active disease or silent asymptomatic 
infection [27].
About 30–80% adults of acute HBV infection shows symptoms (1% fulmi-
nant hepatitis), whereas less than 1 year old children shows no symptoms [28]. 
Symptoms of HBV infection include malaise, dark urine, fever, nausea, jaun-
dice, pale stools, right upper quadrant pain, and anorexia. The risk of chronic 
infection of HBV is hinged on the duration of acquisition [26]. About 90% of 
infected neonates, 30–50% of children aged 1–4 years, and 1–10% of acutely 
infected adults result to persistent infection. There are approximately 15–40% 
with persistent infection that leads to advanced liver disease, cirrhosis, and/or 
HCC [8, 29].
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5. How HBV infection is transmitted
Transmission of HBV in travelers is through percutaneous or mucosal exposure 
to HBV-infected blood or bodily fluids including saliva or semen [30, 31]. There are 
reports of transmission via sexual contact, contaminated blood and its products, 
and contaminated medical equipment and through sharing of infected needles and 
injecting apparatus [31, 32].
In SSA, the viral infection, is often disseminated through perinatal and hori-
zontal route, while in the developed regions, most infections occur in adults of 
younger ages through injecting drug use or high-risk sexual behavior (e.g., bisexu-
als and homosexuals) [8, 33]. HBV infection is known to be transmitted from the 
mother to child and it is a thing of worry [34, 35]. Every year, about 25,000 infants 
are born to HBV-diagnosed mothers in the United States, and approximately 1000 
mothers transmit HBV to their infants. This means that about 90% of HBV-infected 
newborns will eventually develop to chronic infection, and up to 25% of those 
infected at birth will eventually die prematurely due to HBV-related complications. 
Therefore, the standard care for pregnant women includes an HBV testing during 
each pregnancy, to prevent HBV-positive pregnant women from transmitting the 
viral agent to her unborn child [34, 35].
Inadequate infection control in healthcare settings also constitutes to a signifi-
cant mode of HBV transmission. That is why immigrants from many countries are 
recommended to be tested for HBV [12]. Transmission by blood transfusion is now 
rare, whereas before screening of donor blood, it was not uncommon [32]. Cord 
blood is usually negative for the serological markers of HBV, but occasionally intra-
uterine infection might happen. Fetal blood sampling might enhance this risk, but 
amniocentesis does not appear to increase the chances of intrauterine transmission 
[36]. Infection presumably occurs at or soon after birth. It perhaps occurs through 
breast (feeding) milk, as it is known to carry the virus. Transmission could occur 
if there was an in apparent breach in the mucosa of the mouth or during teething 
[37]. Among adults, high-risk sexual activity is one of the most frequent routes 
of transmission for HBV [38]. Historically, male homosexual contacts have been 
associated with a high risk for the viral infection [38]. Sexual transmission accounts 
for a majority of the transmission occurring in adult life [38]. More recently, 
heterosexual transmission is reported to be the most common cause of acute HBV 
infection in adults [39]. Transmission may also continue to occur in healthcare 
settings. It is a result of nonadherence to isolation guidelines in a hemodialysis unit, 
or direct person-person exposure (e.g., surgeon-to-patient or dentist-to-patient) 
may transmit the virus [40]. Sharing of clothes and bed spaces could pose jeopardy 
because the virus could be found in saliva, tears, urine, breast milk, and any other 
body fluid [13]. Other possible means of transmission include an infected parent 
kissing the cut finger or scraped knee of his child and sharing of personal items of 
personal hygiene such as toothbrushes between parents and children [3].
6. Epidemiologic studies of HBV infection in travelers
There is insufficient information that depicts predisposing factors to travelers; 
however, there is scarcity of public reports of HBV infection in travelers, and there 
is low risk for travelers who are not engaged in high-risk behaviors [7]. The risk of 
the viral infection might increase in countries/regions that have a 2% prevalence of 
chronic HBV infection, such as in the African and Western Pacific regions; mis-
sionaries, long-term community development workers, and expatriates might be 
at high risk for the viral agent in such areas [41]. Travelers should take note on how 
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the virus is acquired and take precautionary measures to mitigate transmission. The 
risk of injury due to accident is much higher for travelers than for people in their 
own environment. These injuries may involve medical attention that will require 
injections, IVs, or blood transfusions, thereby enhancing the risk of HBV exposure 
[7]. Older aged travelers, especially those with heart problems, may also require 
medical treatments that will require the same risks of exposure.
The global prevalence of HBV indicated by the proportion of chronic HBV 
carriers in the population that is seropositive for the hepatitis B surface antigen 
(HBsAg) varies strongly between different geographical regions [12]. The virus 
endemicity level is different from one nation to another. The level is mostly lowered 
in the Western Europe, the United States, Canada, and some South American and 
Northern African countries (with an HBsAg chronic carrier rate < 2%); intermedi-
ate (i.e., 2–8%) in Eastern Europe, Central Asia, and some Eastern Asian countries; 
and high (above 8%) in Alaska, Sub-Saharan African countries, and some Asian 
countries [12, 42]. Infection with HBV is considered among the commonest 
immunization preventable infections among immigrants [12, 43]. The prevalence 
of the virus in travelers is associated with the status of the traveler’s immunity, the 
duration of travel, and the level of HBV endemicity in the destination country. 
More so, there are peculiar populations of travelers that might be of higher risk of 
HBV acquisition which includes those visiting relatives and friends, the expatriates, 
dental surgery and medical procedure travelers, and those casual sex engagers [7]. 
Empirical information posited that travelers seeking urgent, unforeseen medical 
attention are common which makes travelers at risk of the viral agent [44]. There is 
paucity of empirical evidence to quantify the risk travelers might also be exposed to 
HBV through activities that involve tattooing, piercings, and acupuncturing [7].
Coppola et al. [42] reported HBsAg seropositivity of 9.6% among undocu-
mented refugees and immigrants in Southern Italy. The study showed that male sex, 
SSA origin, low level of schooling, and minor parenteral risks for acquiring HBV 
infection (acupuncture, tattoo, piercing, or tribal practices) were independently 
associated with ongoing or past HBV infection [42]. A study in Thailand among 
international backpackers reported that 25% of its population had engaged in casual 
sex, while traveling and about half of the population did not often use condom [45]. 
The risk of HBV infection from sex without protection increase with the number 
of sex partners, and the incidence of unprotected sex was higher among the singles 
based on a study carried out on Dutch travelers to tropical and subtropical regions 
[46]. A study among Australian travelers reported that about half of them had 
indulged in at least one activity with an HBV risk during their last overseas trip to 
Southeast or East Asia [47]. Travelers without immunity for the virus traveling to 
high HBV prevalence countries like Nigeria might be at risk of acquiring the infec-
tion due to the many potential accidental and uncontrollable exposures during 
travel. A Netherlands study reported that 9% of all HBV cases between 1992 and 
2003 were travel-related with an estimated incidence of HBV infection of 4.5 per 
100,000 travelers [48]. In a study carried out between 1997 and 2007, HBV infec-
tion was reported in 51 cases of a cohort of ill travelers presenting to GeoSentinel 
clinics [49]. The study also found out that male sex and older age are associated with 
HBV acquisition statistically. Findings among travelers have shown that new sexual 
partners and unprotected sex are common, especially where there is excessive 
alcohol intake environment [44, 50, 51]. In countries with high HBV endemicity, 
the monthly estimated incidence of the infection ranges from 25 per 100,000 for 
symptomatic infections to 80–420 per 100,000 for all HBV infections in susceptible 
expatriates residing in such country [52]. Development/aid workers, volunteers, 
and missionaries pose greater risk of the infection due to extension of travel stay 
and local community close contact [7]. The prevalence of anti-HBc antibody was 
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5%, doubling that of the general population in a Swedish expatriate’s population. 
Short duration of travel stay will obviously lower the risk of the infection [53]. 
Nielsen et al. reported that the incidence per month of HBV infection was 10.2 per 
100,000 with 62% of cases traveling for less than 4 weeks [54]. Most research is 
hinged on travelers becoming sick after travel before testing to occur, so this tends 
to underestimate the incidence of the viral infection [7, 49].
Many cross-sectional research have find out that travelers have reduced baseline 
understanding on infections related to travels and put themselves in jeopardy to 
HBV infection through their actions while in foreign land [47, 55]. Nielsen et al. 
reported that 5% of short-term and 5% nonimmune travelers were under a great 
risk of getting infected with HBV via tattooing, injections, and operation activities 
[44]. About 41% high-risk endeavors were reported among travelers in more than 
6 months with most of the endeavors being unintentional and involuntary [44]. In 
a retrospective study among Australian travelers, 281 (56%) had visited a country 
with medium to high prevalence of HBV, of whom only 43% had been vaccinated 
and 162 (33%) undertook activities associated with potential HBV exposure [55]. 
Medical tourism and transplantation of organs have been identified several times 
as predictors for the viral agent, which highlights that checking for transmissible 
infection cannot be guaranteed universally [56, 57]. A study among Australian 
patients finds out that 2 of 16 who traveled overseas for commercial kidney trans-
plantation developed fulminant hepatitis related to HBV infection and died [58]. 
Significantly high-incidence rate of HBV infection was reported among patients 
receiving renal transplantations in India than in Saudi Arabia [59].
7. Genotypic distribution of HBV
Hepatitis B virus until now has been reported to have 10 genotypes (A–J) with 
identified peculiar distribution based on regions to its high degree of genetic 
heterogeneity [5, 60–62]. HBV genotyping is significant in diverse ways. First, it 
provides global data on the genotypic distribution of the virus including phyloge-
netic and phylogeographic evidence. Second, it justifies the relationship between 
the viral strain and course of disease. It makes us understand the role of human 
migration on the evolution of the virus [63, 64].
One of the three genotypes A, D, and E is predominantly circulating in Africa 
depending on the country. Genotype A is found in the Southern and Eastern 
regions, and genotype D is predominantly circulating in the Northern Africa region. 
Genotype E is more in most of SSA regions including Nigeria; this report excludes 
Uganda and Cameroon which are predominant with the A genotype [5, 60, 64, 65]. 
Genotype A is prevalent in Europe and Southeast Asia, including the Philippines 
[43, 66]. Genotypes B and C are predominant in Asia [67]; genotype D is common 
in the Mediterranean area, the Middle East, and India; genotype F is common in 
Central and South America [66]. Genotype G has been identified in Germany and 
France [67]. Genotype I has been detected in Laos, Vietnam, and China [68, 69], 
while the newest genotype J was identified in the Ryukyu Island in Japan [70, 71].
8. How HBV is diagnosed
HBsAg is the standard diagnostic marker used to screen for HBV infection in 
travelers. A positive test depicts an acute or chronic infection [2]. Quantifying 
HBsAg (qHBsAg) is also an essential tool in staging of HBV infection and predict-
ing responses to HBV treatment. This tool depend on both viral and host factors, 
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such as genotype, preS/S gene variability, and hepatic disease stage [72]. The pres-
ence of hepatitis B envelope antigen (HBeAg) indicates that the virus is actively rep-
licating and typically correlates with higher levels of HBV DNA. Immunoglobulin 
(Ig) G and IgM to hepatitis B core antigen indicates either that the individual has 
previously been infected or has an ongoing infection. IgG anti hepatitis B core 
(IgG anti-HBc) will often persists for life. The presence of anti-HBs shows that the 
individual has obtained immunity either from infection or vaccination [3, 6].
Touching upon the technical procedures behind the tests, tests for serological 
markers are carried out using different techniques, based on resources availability. 
Chemiluminescent microparticle immunoassay (CMIA) is one of those qualita-
tive tests that detect the viral antigen in blood or serum. The technique has a high 
specificity and sensitivity and is based on the antigenic features (e.g., HBsAg or 
HBeAg) binding to commercially synthesized antibodies (anti-HB) with che-
miluminescence [73]. The light produced in a chemiluminescent reaction can be 
measured. This method is more sensitive than the enzyme-linked immunosorbent 
assay (ELISA) [73].
Polymerase chain reaction (PCR) is an advanced technique to detect HBV. It 
amplifies the nucleic acid and greatly enhances the amount of DNA [3]. This 
method can qualitatively or quantitatively detect the amount of HBV DNA in 
patients’ specimen, which reflects the replicative condition of the virus. To 
monitor and manage HBV infection, then a quantitative detection method is the 
technique of choice [73]. ALT levels are measured to help determine liver inflam-
mation. ALT is an enzyme that is normally found in the liver, but also present in 
other body tissue, that is discharged into the circulation system as a consequence 
to hepatocellular injury [26]. ALT plays a role in characterization of HBV infec-
tion phases in synergy with HBV DNA [74]. Different noninvasive diagnoses such 
as aspartate aminotransferase (AST), platelet ratio index (APRI), and transient 
elastography (FibroScan) still exist. APRI is an index to determine the hepatic 
fibrosis based on a formula derived from platelet and AST concentrations [3]. 
FibroScan measures grade of liver fibroses through the detection of liver stiff-
ness. Both methods are recommended by WHO to evaluate cirrhosis presence, 
but while FibroScan is preferred in a context where availability and cost is not an 
issue, APRI is used in settings with limited resources. Liver biopsy has been used to 
assess degree of necroinflammation and fibrosis degrees. However, the method has 
diverse demerits and constraints [6, 75].
9. How HBV infection is prevented and controlled
All travelers should be screened for HBV infection markers, so that they will 
not be at risk of acquiring the virus during stay [74]. Recently updated guidelines 
also recommend that pregnant women with chronic HBV be referred to a specialist 
and considered for HBV treatment to further reduce the chance of transmitting the 
virus [3]. In infants born to HBsAg-positive mothers, the risk of mother-to-child 
transmission is significantly greater if the mother is positive for HBeAg, has a high 
viral load, and/or is infected with HIV [33]. Such infants should be given both vac-
cine and HBIgG (0.5 ml) within 12 hours of delivery. The infants should be evalu-
ated for HBsAg, anti-HBs, and anti-HBc at age 12 months. The presence of anti-HBs 
depicts vaccine-induced immunity, and detection of both anti-HBs and anti-HBc 
shows immunoprophylaxis-modified infection, whereas the presence of HBsAg 
indicates prophylaxis failure [15, 76, 77].
Individuals who have not received the HBV vaccination and are exposed to 
the virus (through needle stick injury, splashing, or sexual exposure to partners 
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infected with the viral agent) should be vaccinated with HBIG (0.04–0.07 ml/kg) 
as soon as possible after exposure. Immunization for the newborn babies should 
start immediately with the initial shot given at a site that is not similar with that for 
HBIG; an accelerated four dose immunization schedule (0, 1, 2, and 12 months) 
is required in the maternal-fetal transmission scenario [8, 77]. HBV can also be 
prevented by avoiding contact with contaminated blood and blood products and 
unprotected sexual exposure. Using condoms has also been shown to reduce the 
chance of sexually transmitted infections [8].
10. Immunization program for travelers
Several reasons why people did not opt for pre-travel vaccinations include trav-
eler’s pre-knowledge regarding the prevention of diseases during overseas travel, 
the limited number of healthcare settings that gives immunization, and that some 
countries have not yet approved the number of vaccines a traveler needs [9, 31].
There are commercially hepatitis B vaccines available currently, for example, 
recombinant HBV vaccine (Engerix-B®, GlaxoSmithKline, and Recombivax 
HB®, Merck & Co., Inc.) and the HAV and HBV combined vaccine (Twinrix®, 
GlaxoSmithKline) [78]. The complete HBV vaccination requires three shots of 
vaccine. The normal timeline of the three intramuscular injections is to have the 
second and third injections given 1 and 6 months after the first dose. An accelerated 
schedule (doses on days 0, 7, and 21 and then a post-travel dose at 12 months) might 
be required if there is an inadequate time for immunization prior to travel [79, 80]. 
An HBV vaccine can also be used to treat persons who have been exposed to the 
virus, in order to prevent disease development [31].
The prevalence of HBV differs between countries and regions, and therefore 
the number of persons acquiring protective immunity from a previous HBV 
infection also changes. Therefore, the recommendation of its vaccination should 
be hinged on likelihood of infection during travel and evidence of previous 
immunization or recovery from previous infection [74]. In those travelers without 
evidence of previous HBV immunity, HBV vaccination is recommended in those 
with HBV exposure risks and traveling to HBV endemic regions [78]. The CDC 
has recommend HBV vaccination to all persons without evidence of immunization 
before traveling to areas with intermediate and high prevalence of chronic hepa-
titis B and, irrespective of the traveler’s destination, and based on the traveler’s 
potential risky activities and exposures [11, 81]. High-risk activities might include 
unprotected sex with a new partner, getting a tattoo or piercing, or having any 
medical procedures like surgery [11, 81]. Studies have reported that only 19% of 
all American travelers and 30% of American travelers planning high-risk activi-
ties had received a completed HBV vaccination before departure irrespective of 
the recommendation made by the CDC [79]. This finding is in consonance with 
information from Europe that only 15% of international travelers to HBV endemic 
regions receive a completed HBV vaccination before travel [79]. There is often a 
very low immunity of HBV to travelers from low endemic regions and those born 
before the EPI schedules [82, 83]. Obviously, there are no recommendations for 
HBV serologic examination of international travelers currently. This might be 
because of the large population of international travelers, thus making it impos-
sible to screen all for the virus. Reports have it that only 3.4–3.9% of the population 
in low endemic countries will have evidence of the HBV serologic markers prior 
infection [82, 83]. Vaccination of those populations should be considered when 
long-term travel is arranged to countries where HBV prevalence is intermediate or 
hyperendemic [31].
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11. Treatment of HBV infection
There are several antiviral treatments available for chronic HBV infection, and 
everyone with chronic HBV should be linked to care, considered for treatment, and 
checked for liver damage and liver cancer regularly [84]. Therapy of HBV reduces 
the amount of virus in the system and lowers the chance of developing to serious 
liver disease and liver cancer. However, most people cannot be cured of the viral 
agent, and as such therapy is recommended to continue for life [85, 86].
Worthy of note is the fact that there are currently two main antiviral drugs for 
the treatment of chronic HBV infection [87]. They are nucleos(t)ide analogues 
(NA) and interferon (IFN) including normal IFNs and pegylated IFNs (Peg-
IFNs). NA gives a direct antiviral effect by stopping DNA polymerase. It is usually 
given orally. There are six types of NAs as approved for treatment of HBV by 
the WHO: Lamivudine (LAM), Adefovir (ADV), Telbivudine (TBV), Entecavir 
(ETV), Tenofovir disoproxil fumarate (TDF), and Tenofovir alafenamide (TAF). 
IFNs, especially the Peg-IFNs, have a suppressed antiviral effect than the NA 
therapy, but its persistent effect can be achieved with a finite therapy. It is usually 
given via subcutaneous injection. There are reports of combination therapy of 
NA + NA and Peg-IFN + NA [86, 87].
There are serious ongoing clinical trials for the development of more effective 
treatments and a cure for HBV infection [3, 6].
12. Way forward in curbing HBV as a traveler’s infection
12.1 Early screening and treatment
Early screening and treatment will help mitigate frequent transmission of the 
viral agent and curb morbidities and mortalities in infected persons [85]. The first 
line should be to give the exact medical advice and start antiviral treatment, if 
available. Sadly, undergoing this step is often a problem in developing regions where 
there is lack of access to good healthcare facilities, and antiviral treatment is often 
exorbitant [6, 86].
12.2 Advocacy of immunization exercise
Advocacy of immunization exercise for HBV infection should be key in elimi-
nating the viral agent worldwide which is central to WHO’s agenda [6, 10]. To 
maximize implementation of the WHO agenda, provision of technical guidance 
and support to reduce transmission of the disease such as adhering to safer blood 
transfusion and disposable needles among others. The virus vaccine is very effective 
in preventing disease progression. It has been reported that only 27% of newborn 
babies had receive a birth dose of hepatitis B vaccine globally [86]. Birth dose vacci-
nation of the viral agent is fundamental to halting mother-to-child transmission as 
late immunization is not fully effective in destroying the chain of mother-to-child 
transmission. Coordination between maternal health services and immunization 
should be effectively established [88].
12.3 Self-protection measures
Self-protection measures are one of the pre-travel counseling given to poten-
tial travelers to HBV and other blood-borne pathogen endemic regions [7, 8, 43]. 
Persons should be guided from contaminated items or equipment used in medical 
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or cosmetic procedures, blood products, injection drug use or any exercise that 
involve piercing the skin or mucosa, or unprotected sexual activity. Travelers should 
be advised properly against the use of equipment that is not properly sterilized or 
disinfected on medical or beautification tourism (such as tattooing or piercing) [8]. 
The viral agent can be disseminated to others if tools are not sterile or if personnel 
do not follow proper infection control protocols [89].
12.4 Educational awareness
Educational awareness and programs that will be targeted towards HBV aware-
ness lowers transmission of the infection [90, 91]. There is a large pool of persons 
suffering from chronic HBV infection in Sub-Saharan Africa that are not aware of 
their situation. Educational awareness and implementation of local health measures 
are pertinent in eradicating the scourge of the infection [2]. These should include 
training local communities on how to perform safe blood transfusion and establish-
ing efficient screening methods for transfusion of donated bloods. Health education 
programs should include administration of safe injections (intravenous drug users 
and healthcare settings) and implementation of safer sex practices (especially the 
use of condoms). More so, occupational safety trainings should be advocated for 
health workers [92]. It is also worthy to note that effective communication and 
emphasizing the role of the virus testing, follow-up visits, and monitoring therapy 
will help eliminate HBV infection [43].
12.5 Socioeconomic condition enhancement
Enhancing the socioeconomic conditions of a particular population has shown 
reduction in the rate of HBV infection. Government and non-governmental orga-
nization (NGO) bodies should ensure that there is a universal access to portable 
water and encourage food handling that is safe and hygienic [92]. They should also 
implement good sanitation systems. Safe disposal practice of medical waste should 
be advocated in the health settings [43].
13. Conclusion
There are ongoing development of two novel anti-HBV drugs, namely, Besifovir 
and Myrcludex-B that will soon be in the market [3]. The infection is one of those 
preventable infections by immunization in travelers. Therefore, travelers should 
often be screened and immunized for HBV infection before traveling to endemic 
countries because immigrants and/or travelers who have the viral infection pose a 
great risk of HCC and death. They as well serve as transmitters of the viral agent to 
those not infected when returned from travel. Continuous health surveillance and 
strict checking of migrants to ascertain previous vaccination evidence will go a long 
way in mitigating the infection across travelers. There is no single measure strong 
enough to curb viral hepatitis epidemics, but having a global vision and implement-
ing multiple strategies will go a long way towards eliminating HBV infection and 
other global disease burden in 2030.
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